The 2nd sialic acid-binding site of influenza A virus neuraminidase is an important determinant of the hemagglutinin-neuraminidase-receptor balance.


Journal

PLoS pathogens
ISSN: 1553-7374
Titre abrégé: PLoS Pathog
Pays: United States
ID NLM: 101238921

Informations de publication

Date de publication:
06 2019
Historique:
received: 03 01 2019
accepted: 22 05 2019
revised: 20 06 2019
pubmed: 11 6 2019
medline: 4 12 2019
entrez: 11 6 2019
Statut: epublish

Résumé

Influenza A virus (IAV) neuraminidase (NA) receptor-destroying activity and hemagglutinin (HA) receptor-binding affinity need to be balanced with the host receptor repertoire for optimal viral fitness. NAs of avian, but not human viruses, contain a functional 2nd sialic acid (SIA)-binding site (2SBS) adjacent to the catalytic site, which contributes to sialidase activity against multivalent substrates. The receptor-binding specificity and potentially crucial contribution of the 2SBS to the HA-NA balance of virus particles is, however, poorly characterized. Here, we elucidated the receptor-binding specificity of the 2SBS of N2 NA and established an important role for this site in the virion HA-NA-receptor balance. NAs of H2N2/1957 pandemic virus with or without a functional 2SBS and viruses containing this NA were analysed. Avian-like N2, with a restored 2SBS due to an amino acid substitution at position 367, was more active than human N2 on multivalent substrates containing α2,3-linked SIAs, corresponding with the pronounced binding-specificity of avian-like N2 for these receptors. When introduced into human viruses, avian-like N2 gave rise to altered plaque morphology and decreased replication compared to human N2. An opposite replication phenotype was observed when N2 was combined with avian-like HA. Specific bio-layer interferometry assays revealed a clear effect of the 2SBS on the dynamic interaction of virus particles with receptors. The absence or presence of a functional 2SBS affected virion-receptor binding and receptor cleavage required for particle movement on a receptor-coated surface and subsequent NA-dependent self-elution. The contribution of the 2SBS to virus-receptor interactions depended on the receptor-binding properties of HA and the identity of the receptors used. We conclude that the 2SBS is an important and underappreciated determinant of the HA-NA-receptor balance. The rapid loss of a functional 2SBS in pandemic viruses may have served to balance the novel host receptor-repertoire and altered receptor-binding properties of the corresponding HA protein.

Identifiants

pubmed: 31181126
doi: 10.1371/journal.ppat.1007860
pii: PPATHOGENS-D-18-02468
pmc: PMC6586374
doi:

Substances chimiques

Receptors, Virus 0
Viral Proteins 0
NA protein, influenza A virus EC 3.2.1.18
Neuraminidase EC 3.2.1.18
N-Acetylneuraminic Acid GZP2782OP0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

e1007860

Déclaration de conflit d'intérêts

The authors have declared that no competing interests exist.

Références

Science. 2007 Feb 2;315(5812):655-9
pubmed: 17272724
J Gen Virol. 2010 Sep;91(Pt 9):2322-30
pubmed: 20505010
Anal Chem. 2012 Oct 16;84(20):8650-5
pubmed: 22985263
J Gen Virol. 1995 Jul;76 ( Pt 7):1719-28
pubmed: 9049377
Anal Biochem. 1979 Apr 15;94(2):287-96
pubmed: 464297
Proc Natl Acad Sci U S A. 2011 Aug 23;108(34):14264-9
pubmed: 21825167
Int J Mol Sci. 2017 Jul 17;18(7):
pubmed: 28714909
FEBS Lett. 1975 Feb 15;50(3):296-9
pubmed: 1116600
J Biol Chem. 1979 Feb 10;254(3):789-95
pubmed: 83994
J Biol Chem. 2011 Feb 18;286(7):5868-75
pubmed: 21173148
J Virol. 2015 Dec;89(23):12211-6
pubmed: 26378170
J Gen Virol. 2017 Jun;98(6):1274-1281
pubmed: 28612701
Influenza Other Respir Viruses. 2012 Jul;6(4):245-56
pubmed: 22085243
Virology. 1994 Nov 15;205(1):17-23
pubmed: 7975212
J Virol. 2017 May 12;91(11):
pubmed: 28356530
Virology. 1984 Sep;137(2):314-23
pubmed: 6485252
Glycoconj J. 2006 Feb;23(1-2):85-92
pubmed: 16575525
Emerg Infect Dis. 2017 Feb;23(2):220-231
pubmed: 27869615
Virology. 2001 Mar 15;281(2):156-62
pubmed: 11277689
J Virol. 2016 Sep 29;90(20):9457-70
pubmed: 27512075
PLoS One. 2010 May 14;5(5):e10645
pubmed: 20498717
Virology. 1991 Aug;183(2):496-504
pubmed: 1853557
Biologicals. 2001 Mar;29(1):27-37
pubmed: 11482890
Trends Microbiol. 2016 Dec;24(12):991-1001
pubmed: 27491885
Clin Microbiol Infect. 2016 Dec;22(12):975-983
pubmed: 27424943
Virology. 2011 Jun 20;415(1):12-9
pubmed: 21501853
Virology. 2007 May 10;361(2):384-90
pubmed: 17207830
Arch Biochem Biophys. 1993 Jul;304(1):65-73
pubmed: 8323299
J Biol Chem. 1980 Oct 25;255(20):9713-8
pubmed: 7430095
Cell Host Microbe. 2017 Mar 8;21(3):356-366
pubmed: 28279346
BMC Biotechnol. 2008 Apr 18;8:41
pubmed: 18423015
Glycobiology. 1998 Oct;8(10):1007-12
pubmed: 9719681
Glycoconj J. 2007 Dec;24(9):591-604
pubmed: 17805962
J Clin Microbiol. 2005 Aug;43(8):4139-46
pubmed: 16081961
Emerg Microbes Infect. 2019;8(1):327-338
pubmed: 30866786
J Virol. 2014 Aug;88(16):9197-207
pubmed: 24899180
Virology. 1996 Mar 15;217(2):452-8
pubmed: 8610436
Virol J. 2013 Nov 22;10:321
pubmed: 24261589
J Virol. 2017 Apr 13;91(9):
pubmed: 28202753
Sci Rep. 2016 Nov 09;6:36826
pubmed: 27827454
Nature. 2006 Sep 7;443(7107):45-9
pubmed: 16915235
J Biol Chem. 1988 Dec 15;263(35):18911-9
pubmed: 3143719
Vet Microbiol. 2000 May 22;74(1-2):71-5
pubmed: 10799779
Virology. 2005 Apr 10;334(2):276-83
pubmed: 15780877
J Mol Biol. 2006 Feb 3;355(5):1143-55
pubmed: 16343533
J Virol. 2000 Sep;74(18):8502-12
pubmed: 10954551
Virol J. 2006 Aug 31;3:63
pubmed: 16945126
J Virol. 2012 Sep;86(17):9221-32
pubmed: 22718832
Bioessays. 2003 Jul;25(7):657-71
pubmed: 12815721
Biochemistry (Mosc). 2015 Jul;80(7):872-80
pubmed: 26542001
Proc Natl Acad Sci U S A. 1997 Oct 28;94(22):11808-12
pubmed: 9342319
J Virol. 1997 Sep;71(9):6706-13
pubmed: 9261394
Virology. 1991 Jan;180(1):10-5
pubmed: 1984642
Cell Host Microbe. 2017 Jan 11;21(1):23-34
pubmed: 28017661
Acta Naturae. 2009 Jul;1(2):26-32
pubmed: 22649600
Glycobiology. 2011 Aug;21(8):988-93
pubmed: 21863598
J Biol Chem. 1987 Feb 5;262(4):1596-601
pubmed: 3805045
Biochemistry. 1989 Oct 17;28(21):8388-96
pubmed: 2605190
PLoS One. 2012;7(7):e38665
pubmed: 22808012
J Virol. 1987 Sep;61(9):2910-6
pubmed: 3612957
J Virol. 2018 Sep 26;92(20):
pubmed: 30089692
Anal Biochem. 1999 Nov 15;275(2):171-9
pubmed: 10552901
Nat Commun. 2013;4:1491
pubmed: 23422659
J Virol. 1995 Aug;69(8):5011-7
pubmed: 7541844
Arch Virol. 2009;154(6):945-57
pubmed: 19458903
Angew Chem Int Ed Engl. 2012 Feb 27;51(9):2221-4
pubmed: 22281708
J Virol. 1999 Aug;73(8):6743-51
pubmed: 10400772
J Virol. 1996 Aug;70(8):5519-24
pubmed: 8764064
J Virol. 2010 Jul;84(13):6769-81
pubmed: 20410266
PLoS Pathog. 2018 Aug 13;14(8):e1007233
pubmed: 30102740

Auteurs

Wenjuan Du (W)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Hongbo Guo (H)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Vera S Nijman (VS)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Jennifer Doedt (J)

Institute of Virology, Philipps University, Marburg, Germany.

Erhard van der Vries (E)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Joline van der Lee (J)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Zeshi Li (Z)

Department of Chemical Biology and Drug Discovery, Utrecht University, Utrecht, the Netherlands.

Geert-Jan Boons (GJ)

Department of Chemical Biology and Drug Discovery, Utrecht University, Utrecht, the Netherlands.

Frank J M van Kuppeveld (FJM)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Erik de Vries (E)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Mikhail Matrosovich (M)

Institute of Virology, Philipps University, Marburg, Germany.

Cornelis A M de Haan (CAM)

Virology Division, Faculty of Veterinary Medicine, Utrecht University, Utrecht, The Netherlands.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH